516 related articles for article (PubMed ID: 20623347)
1. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II.
Pais P
Adv Ther; 2010 Aug; 27(8):555-63. PubMed ID: 20623347
[TBL] [Abstract][Full Text] [Related]
2. Determination of the potency of a novel saw palmetto supercritical CO2 extract (SPSE) for 5α-reductase isoform II inhibition using a cell-free in vitro test system.
Pais P; Villar A; Rull S
Res Rep Urol; 2016; 8():41-9. PubMed ID: 27186566
[TBL] [Abstract][Full Text] [Related]
3. A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and Saw Palmetto lipid extract in vitro.
Anderson ML
J Herb Pharmacother; 2005; 5(1):17-26. PubMed ID: 16093232
[TBL] [Abstract][Full Text] [Related]
4. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
5. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
6. Serenoa repens extracts: In vitro study of the 5α-reductase activity in a co-culture model for Benign Prostatic Hyperplasia.
Buonocore D; Verri M; Cattaneo L; Arnica S; Ghitti M; Dossena M
Arch Ital Urol Androl; 2018 Sep; 90(3):199-202. PubMed ID: 30362688
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of combination of Stauntonia hexaphylla and Cornus officinalis on testosterone-induced benign prostatic hyperplasia through inhibition of 5α- reductase type 2 and induced cell apoptosis.
Karunasagara S; Hong GL; Jung DY; Kim KH; Cho K; Jung JY
PLoS One; 2020; 15(8):e0236879. PubMed ID: 32790676
[TBL] [Abstract][Full Text] [Related]
8. Effects of dietary saw palmetto on the prostate of transgenic adenocarcinoma of the mouse prostate model (TRAMP).
Wadsworth TL; Worstell TR; Greenberg NM; Roselli CE
Prostate; 2007 May; 67(6):661-73. PubMed ID: 17342743
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
10. 5alpha-reductase activity in the prostate.
Steers WD
Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
[TBL] [Abstract][Full Text] [Related]
11. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
[TBL] [Abstract][Full Text] [Related]
12. An overview on 5alpha-reductase inhibitors.
Aggarwal S; Thareja S; Verma A; Bhardwaj TR; Kumar M
Steroids; 2010 Feb; 75(2):109-53. PubMed ID: 19879888
[TBL] [Abstract][Full Text] [Related]
13. Effect of permixon on human prostate cell growth: lack of apoptotic action.
Hill B; Kyprianou N
Prostate; 2004 Sep; 61(1):73-80. PubMed ID: 15287095
[TBL] [Abstract][Full Text] [Related]
14. Role of 5α-reductase inhibitors in benign prostatic diseases.
Azzouni F; Mohler J
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):222-30. PubMed ID: 22333687
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 5α-reductase inhibitory activity of certain herbs useful as antiandrogens.
Nahata A; Dixit VK
Andrologia; 2014 Aug; 46(6):592-601. PubMed ID: 23710567
[TBL] [Abstract][Full Text] [Related]
16. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1.
Issa S; Schnabel D; Feix M; Wolf L; Schaefer HE; Russell DW; Schweikert HU
J Clin Endocrinol Metab; 2002 Dec; 87(12):5401-7. PubMed ID: 12466325
[TBL] [Abstract][Full Text] [Related]
17. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
[TBL] [Abstract][Full Text] [Related]
18. Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders.
Paba S; Frau R; Godar SC; Devoto P; Marrosu F; Bortolato M
Curr Pharm Des; 2011; 17(2):151-67. PubMed ID: 21361868
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
Ranjan M; Diffley P; Stephen G; Price D; Walton TJ; Newton RP
Life Sci; 2002 May; 71(2):115-26. PubMed ID: 12031682
[TBL] [Abstract][Full Text] [Related]
20. Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia.
Krishnamoorthi R; Ganapathy A A; Hari Priya VM; Kumaran A
J Ethnopharmacol; 2024 Aug; 330():118207. PubMed ID: 38636573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
